Amaria Highlights Phase 1 Trial of OBX-115 in Melanoma
Source: Targeted Oncology, March 2025
According to Amaria, early data from the phase 1 study, including findings presented at the 2024 American Society of Clinical Oncology Annual Meeting were encouraging, as OBX-115 was shown to be well-tolerated and did not lead to any severe adverse events.
The agent also demonstrated significant antitumor activity, leading to durable responses in half of the patients studied, including 2 complete remissions and 1 partial remission.
Previously in September 2024, the FDA granted a regenerative medicine advanced therapy designation to OBX-115 for the treatment of patients with unresectable or metastatic melanoma that has been resistant to immune checkpoint inhibitor therapy. In July 2024, the FDA also granted the agent fast track designation.